3 Result: IBio
Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
October 02nd, 2023
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more
Triple Impact: iBio's Collaboration, Oracle's Strong Q4, and EVgo's Charging Network Growth Make Waves
June 12th, 2023
iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more
Lucintel Forecasts Feed Enzyme Market to grow at a CAGR of 9% from 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Feed Enzyme Market is projected to grow at a CAGR of 9% from 2019 to 2024. Growth in this market is primarily driven by increasing animal population, high cost of. Read more
Want To Find Some News?
News By Industries
Recent Post
-
NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025Earnings Preview: Amicus Therapeutics, ANSYS, and Etsy Take Center Stage
February 16th, 2025
Member Login